InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP
Shots:
- The first patient has been dosed in a P-II clinical trial to evaluate orelabrutinib (BTK inhibitor) in patients with ITP in China. The therapy is also being studied for MS & SLE
- The studies showed that 70% of patients respond to 1L treatments, some patients are still r/r after combined therapies. The therapy may reduce platelet destruction by inhibiting B cell activation & autoantibody production & has high target selectivity with a safety profile
- Orelabrutinib had received BTD from the US FDA for r/r MCL & NMPA’s approval for r/r CLL / SLL & for r/r MCL. The therapy is currently undergoing in the US & China as monothx. or in combination therapies for MZL, CNSL, WM & DLBCL
Ref: PR Newswire | Image: Innocare
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
